Distinctive Epigenomic Alterations in NF1-deficient Cutaneous and Plexiform Neurofibromas Drive Differential MKK/p38 Signaling

Jamie L. Grit  
Van Andel Research Institute: Van Andel Institute

Benjamin K. Johnson  
Van Andel Research Institute: Van Andel Institute

Patrick S. Dischinger  
Van Andel Research Institute

Curt J. Essenburg  
Van Andel Research Institute

Marie Adams  
Van Andel Research Institute

Stacy Campbell  
Spectrum Health Medical Group

Kai Pollard  
Johns Hopkins Medical Institutions: Johns Hopkins Medicine

Christine A. Pratilas  
Johns Hopkins Medical Institutions: Johns Hopkins Medicine

Tim J. Triche  
Van Andel Research Institute: Van Andel Institute

Carrie R. Graveel  
Van Andel Research Institute

Matt Steensma (✉ matthew.steensma@spectrumhealth.org)  
Van Andel Research Institute  https://orcid.org/0000-0002-9003-6730

Research

Keywords: Epigenome, neurofibromatosis, neurofibroma, inflammation, RAS

DOI: https://doi.org/10.21203/rs.3.rs-78134/v1

License: ©  This work is licensed under a Creative Commons Attribution 4.0 International License.  
Read Full License
Abstract

Benign peripheral nerve sheath tumors are the clinical hallmark of Neurofibromatosis Type 1. They account for substantial morbidity and mortality in NF1. Cutaneous (CNF) and plexiform neurofibromas (PNF) share nearly identical histology but maintain different growth rates and risk of malignant conversion. The reasons for this disparate clinical behavior are not well explained by recent genome or transcriptome profiling studies. We hypothesized that CNFs and PNFs are epigenetically distinct tumor types that exhibit differential signaling due to genome-wide and site-specific methylation events. We interrogated the methylation profiles of 45 CNFs and 17 PNFs from NF1 subjects with the Illumina EPIC 850K methylation array. Based on these profiles, we confirm that CNFs and PNFs are epigenetically distinct tumors with broad differences in higher order chromatin states and specific methylation events altering genes involved in key biological and cellular processes, such as inflammation, RAS/MAPK signaling, actin cytoskeleton rearrangement, and oxytocin signaling. Based on our identification of two separate DMRs associated with alternative leading exons in MAP2K3, we demonstrate differential RAS/MKK3/p38 signaling between CNFs and PNFs. Epigenetic reinforcement of RAS/MKK/p38 was a defining characteristic of CNFs leading to pro-inflammatory signaling and chromatin conformational changes, whereas PNFs signaled predominantly through RAS/MEK. Tumor size also correlated with specific CpG methylation events. Taken together, these findings confirm that NF1 deficiency influences the epigenetic regulation of RAS signaling fates, accounting for observed differences in CNF and PNF clinical behavior. The extension of these findings is that CNFs may respond differently than PNFs to RAS-targeted therapeutics raising the possibility of targeting p38-mediated inflammation for CNF treatment.

Introduction

Approximately 1 in 3,000 live births are affected by the tumor predisposition condition, Neurofibromatosis Type 1 (NF1) making it the most common single gene-inherited condition in humans. One of the clinical hallmarks and diagnostic sine qua non of NF1 is the formation of benign peripheral nerve tumors called, neurofibromas. Neurofibromas are a major cause of disfigurement, pain, and morbidity in NF1. These issues are predominantly attributable to two types of neurofibromas: dermal or cutaneous neurofibromas (CNFs) that develop in the skin, and plexiform neurofibromas (PNFs) that arise from nerves situated in deeper anatomic compartments. Even though CNFs and PNFs share similar histology, they are pathophysiologically distinct. NF1-related PNFs are associated with the development of high grade malignant peripheral nerve sheath tumors (MPNSTs), which are the leading cause of death of NF1 patients\(^1\). In contrast, CNFs exhibit slower growth rates and do not have malignant potential\(^2\)-\(^4\). Although CNFs do not become malignant, these benign tumors are often painful and disfiguring. These critical distinctions between CNFs and PNFs are not explained by genomic and transcriptomic studies that failed to identify consistent alterations in these tumors\(^5\).

NF1 loss of heterozygosity is thought to be the initiating event in CNF and PNF formation, making NF1 the most commonly mutated gene in these tumors. Other genetic alterations have also been described but are inconsistent between and across tumor types. Previous genomic studies observed that
approximately one third of CNFs exhibit focal chromosomal imbalance; however, there were no consistent chromosomal microstructure alterations among the samples analyzed\(^6\). Expression profiling studies have yielded mixed results as to whether CNFs and PNFs can be distinguished based on gene expression alone\(^5,7\). It is important to note that these studies were not powered specifically to address differences between CNFs and PNFs, but rather focused on distinguishing PNFs and MPNSTs. Even though CNFs and PNFs arise in distinct anatomic sites, mouse models have demonstrated that CNFs and PNFs share a common cell of origin in Schwann cell progenitors (i.e. skin-derived precursor (SKP)\(^8\) or GAP43 + PLP + precursors)\(^9\). Currently, it is not well understood how tumor microenvironment impacts neurofibroma progression\(^10\), however inflammation from \textit{NF1} haploinsufficient mast cells is requisite for PNF development\(^11\). Prior work examining epigenetic modifications in CNFs and PNFs has also been confounded by the lack of tissue- and patient-matched controls which are not always available in the context of \textit{NF1} deficiency. Thus, there are insufficient data to adequately explain why CNFs and PNFs exhibit such distinct clinical behavior.

In this study, we performed genome-wide DNA methylation profiling using the Illumina Infinium MethylationEPIC BeadChip platform on a large cohort of CNFs and PNFs. We demonstrate that CNFs and PNFs maintain epigenetically distinct profiles that are distinguishable based on both site-specific and chromosome-wide methylation differences. This work stands in contrast to prior studies that failed to identify differential methylation at the \textit{NF1} locus in peripheral nerve sheath tumors, and were underpowered to identify signaling impacts based on genome-wide methylation differences\(^12,13\). Our work confirms that broad and distinct patterns of methylation result in differential signaling between CNFs and PNFs, as well as in the regulation of tumor size. Specifically, two differentially methylated regions (DMRs) in the \textit{MAP2K3} and an upstream regulatory site for \textit{MAPK14} were significantly altered between CNFs and PNFs leading to increased MKK3 and p38 expression. This epigenetic reinforcement of MKK3 and p38 expression also led to activation of both p38 and ERK in a validation cohort of CNFs. The MKK3/ p38 signaling axis is linked to both inflammation and pain signaling, as well as chromatin conformational changes through SWI/SNF complex regulation. ERK activation is not a usual consequence of MKK3/p38 activation due to conserved inhibitory feedback pathways. Taken together, our data confirm that epigenetic regulation of key RAS signaling genes results in disordered growth, inflammation and signaling in the context of NF1 deficiency. These findings also confirm the importance of epigenetic regulation in CNF tumor initiation and progression, as well as a potentially druggable signaling axis in MKK3/p38/ERK.

### Results

**CNFs and PNFs have distinct global methylation profiles**

CNFs are benign, skin-based neoplasms. These tumors typically arise in puberty and increase in number throughout adulthood. NF1 patients can develop between several to thousands of CNFs that cover significant portions of the body. Even though the size of CNFs can vary in NF1 patients (Fig. 1a), CNFs
are associated with limited growth potential (typically < 3 cm). The primary treatment option for CNFs is surgical removal, however they are prone to recurrence and surgical treatment is impossible in patients with severe tumor burden. CNFs are composed of neoplastic Schwann cells, mast cells, and fibroblasts (Fig. 1a, middle and lower panels). In addition, CNFs often include a collagenous and myxoid extracellular matrix. CNFs and PNFs share nearly identical histology and require clinical context to accurately diagnosis. In contrast, PNF growth is dysregulated, can develop anywhere in the body, and typically extends along peripheral nerves. Because of these features, PNFs can envelop organs and cause pain, disfigurement, and morbidity. For example, a PNF included in this study was removed due to its rapid growth in an axial location (Fig. 1b). Importantly, CNF-associated malignancies are rare, whereas PNFs are able to dedifferentiate into aggressive sarcomas in 8–13% of patients.

In order to confirm whether CNFs and PNFs are genomically and transcriptomically distinct lesions using advanced sequencing techniques, we compared publicly available RNAseq data from an NF1 test cohort where cutaneous/non-plexiform neurofibromas were compared to PNFs. Principal Component Analysis (PCA) of the RNA-seq data confirmed that histologically identical cutaneous CNFs and PNFs cannot be discriminated based on global gene expression profiles, largely due to transcript heterogeneity (Fig. 1c). Prior expression profiling studies using cDNA microarrays did not identify distinct CNF and PNF transcriptome signatures at the macro level, even though individual differences in key gene expression were identified. We also evaluated whether genomic differences were present among our CNF and PNF cohorts and did not observe any large-scale differences in copy number variation (Fig. 1d). These results verify that few distinctive genomic or transcriptome alterations exist outside of putative NF1 deficiency (Fig. 1c-d).

DNA methylation changes play key roles in development, disease and aging, with the added benefit of being a highly stable epigenetic mark that can be readily assayed, making this a clinically actionable and functional readout. We determined neurofibroma methylation profiles using the Infinium MethylationEPIC array in a discovery cohort of 62 CNF and PNF samples from a total of 38 patients. The MethylationEPIC array is a targeted approach to interrogate approximately 850,000 methylation sites throughout the genome, including coding and regulatory space (e.g. FANTOM5 annotated enhancers) in addition to CpG islands, shores, and shelves. We applied a hierarchical generalized linear mixed effects model to identify differentially methylated loci between CNFs and PNFs, controlling for age and sex differences with a nested random effect to control for partially repeated measures. In total, we identified 31,201 significant differentially methylated probes (DMP; q < 0.05). By examining differentially methylated loci with an absolute odds ratio greater than 4 and clustering using a semi-supervised hierarchical approach, we establish a distinct, base-pair resolution epigenetic signature for CNF and PNFs (Fig. 1e). This probe-based analysis confirms that individual CpG-based methylation events are highly consistent within CNF and PNF tumor types, yet between CNFs and PNFs there are clearly definable, distinct global methylation profiles with minimal overlap. Comparison of beta values within clustered methylation sites revealed striking differences across large portions of the genome suggesting that chromatin architecture is also distinct between tumor types.
CNFs and PNFs display distinctive 3D chromatin architecture

Next, we sought to determine if nuclear organization and higher-ordered chromatin states differed between CNFs and PNFs. Chromosomal DNA is organized into A/B compartments that largely correspond to being either transcriptionally active DNA compartments (A compartment) or silenced DNA compartments (B compartment). As such, DNA compartmentalization is a critical determinant of gene expression leading to cell fate determination and coordinated tissue development. Typically, chromatin compartments are identified using HiC or other assays to directly measure long-range chromatin contacts. However, it has been demonstrated that Infinium Human Methylation 450 k or EPIC array can reconstruct higher-order chromatin structure similar to HiC. Thus, we inferred A/B group-level compartments in CNF and PNFs at 100 kb resolution. We show that the 3D genomic organization between CNFs and PNFs is 80–85% concordant whereas 15–20% of the compartments are inverted or discordant between CNF and PNFs. This discordance of PNF and CNFs compartments is observed genome-wide (X chromosomes were not assessed) (Fig. 2a and 2c). These data provide additional support that CNFs and PNFs possess distinct epigenomes. Given that individual CpG methylation changes and associated effects are difficult to interpret in isolation unless they are placed in the context of neighboring CpG loci and summarized into region-level changes, we used the differentially methylated probes identified above to call 6,097 significantly differentially methylated regions (DMRs; q < 0.05) using DMRcate. A focused evaluation of the top 250 DMRs in terms of fold change revealed that 100 sites were strongly associated with gene regulation (i.e promoter/enhancer space) (Fig. 2b). We observed that areas of promoter/enhancer overlap were evenly distributed across all chromosomes except chromosome 17 which was disproportionately affected (Fig. 2b-d). Discordant regulatory DMRs spanned the entire length of Chromosome 17, including key genes such as NF1, TP53, and MAP2K3 (Fig. 2d). Taking into account all DMRs, chromatin structural analysis revealed a broad distribution that extended well beyond the transcriptional start site, including CpG islands, shores, and shelves (Fig. 2e). Taken together, these results provide evidence that NF1-deficiency in transcriptionally and genomically similar lesions can alter 3D genomic organization and higher order chromatin structure. These results strongly link NF1-deficiency with differential methylation events that alter signaling fates and result in broad remodeling of chromatin architecture throughout the genome. They also strongly suggest that methylation events contribute to the morphological and pathological variation observed in NF1 patients.

CNF size variation is correlated with differential methylation

The degree of CNF involvement is highly variable among NF1 patients with poor genotype-phenotype correlation. CNF density is even noted to be discordant among monozygotic twins. To determine whether CNF size correlates with site-specific methylation events, we collected CNFs in three size categories. Adjusting for age and sex differences, we determined significant associations (q < 0.05) between CNF size in millimeters and probe-level methylation status. A total of 188 loci were found to be statistically significant. Both positive and negative correlations were discovered among the 188
associated loci, with 34 achieving an effect size (> 4 mm) that reached statistical significance (Fig. 3). Signaling pathway correlation of the 34 significant DMRs was not possible due to a lack of statistical confidence, however these results indicate that CNF size is significantly influenced by methylation of specific loci.

**Differentially methylated loci are enriched in inflammatory pain and RAS pathways**

To understand how the distinct methylation patterns may promote CNF and PNF development, we performed a gene ontology analysis to determine whether DMR patterns would predict signaling in critical pathways. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis is a high-level functional analysis of epigenomic data that allows for annotation of key cell signaling and biological processes. KEGG analysis of global DMR data identified several key cellular processes that differed significantly between tumor types as a result of predicted expression impacts from methylation events. As expected, the RAS, MAPK, and PI3K-AKT signaling pathways were associated with both CNF and PNF development; however, differential methylation was noted between the tumor types in genes affecting key cellular processes. Interestingly, CNFs and PNFs demonstrated differential regulation of inflammatory mediators of transient receptor potential (TRP) channels, phospholipase D (PLD), cytoskeletal rearrangement, and oxytocin signaling (Fig. 4a). TRP channels, PLD, and oxytocin signaling have all been demonstrated to regulate inflammation and pain which is a common feature of both PNFs and CNFs. Pain and inflammation is known to be dysregulated in Neurofibromatosis, however it is unclear how NF1 deficiency exacerbates these symptoms. To functionalize these results and validate a role for individual DNA methylation events in tumor-type associated inflammation and pain signaling, we examined significantly correlated DMRs associated with genes in the Inflammatory Mediator Regulation of TRP Channels KEGG pathway. Two highly significant DMRs (DMR1 p = 2.72E-21; DMR2 p = 1.84E-08) were discovered within the primary and alternative promotors and leading exons of the MAP2K3 gene that encodes the MAP kinase kinase, MKK3 (Fig. 4b). Across DMR1, PNFs displayed higher DNA methylation, while CNFs were more highly methylated in DMR2 (Fig. 4c). As MKK3 plays a role in pain signaling, inflammation and cancer,28,29 we hypothesized that reciprocal methylation of DMR1 and DMR2 would instruct differential MKK3 protein expression leading to altered RAS signaling fates. Western blot of a representative subset of CNF and PNF tumors demonstrated that MKK3 expression was highly correlated to MAP2K3 DMR methylation status (DMR1:MKK3 p = 0.85, p = 0.00018) (Fig. 4d,e) despite expected intra- and inter-tumoral heterogeneity. This strong inverse correlation points to exquisite control of MKK3 expression through methylation events occurring at sites of alternative leading MAP2K3 exons.

As p38 is the primary effector of MKK3 signaling in response to cellular stress and cytokine stimulation, as well as chromatin conformational changes such as those observed in Fig. 2, we hypothesized that DNA methylation also regulates p38 expression in CNFs and PNFs. Because methylation events can also impact protein kinase activation states,31 we also assessed whether MAP2K3 methylation events...
affected downstream p38 expression and activation. We identified a significant DMR ($p = 1.66E-16$) approximately 3.5 kb upstream of the MAPK14 gene, which encodes the p38α isoform. Although the DMR lies within the promotor region of SLC26A8 gene, p38 protein levels were negatively correlated with methylation at this site ($p = -0.56, p = 0.038$) (Fig. 5a,b). Methylation was higher in the PNF group than the CNF group leading to variable but overall decreased p38 expression (T180/T182) in PNFs (Fig. 5a). More specifically, CNFs expressed both MKK3 (Fig. 4d) and p38 (Fig. 5a) more abundantly than PNFs, as well as phospho-p38 indicating consistent p38 activation (Fig. 5c). These results are consistent with canonical MKK3/P38 pathway activation. Whereas MKK3 maintains a high degree of specificity for p38, it is unclear whether p38 regulates ERK through direct crosstalk. P38 activation was previously shown to inhibit RAS through a redundant negative feedback loop originating in downstream MAPK signaling. It is currently unclear how NF1 deficiency affects negative feedback mechanisms downstream of RAS. We demonstrate that p38 activation was strongly correlated with pERK expression regardless of tumor type ($p = 0.70, p = 0.006$) (Fig. 5d). These results point to discrete signaling differences between RAS/MEK/ERK and RAS/MKK3/ p38/ERK in the context of NF1 deficiency (Fig. 5c,d).

**Discussion**

This study represents the most comprehensive epigenetic analysis of CNFs and PNFs to date. Greater than 99% of NF1 patients exhibit both CNFs and PNFs over the course of their lifetime accounting for a substantial negative impact on quality of life. Pain is a constant feature of both neurofibroma subtypes, yet how pain signaling occurs in peripheral nerve tumors is poorly understood. Despite the recent demonstration of MEK inhibitor effectiveness in PNF treatment, it is unclear whether CNFs respond with equal efficacy. More therapies are needed to treat neurofibroma tumor progression and symptoms, such as pain and itching, as all of these clinical features contribute significantly to morbidity in NF1. Our findings address an unmet clinical need for neurofibroma treatment and offer significant mechanistic insight into how benign nerve tumors initiate, progress, and generate symptoms through epigenetic means. It is now conceivable that NF1-deficient neurofibromas can be treated by targeting epigenetic mechanisms that reinforce RAS signaling.

In the absence of distinctive transcriptomic or genomic alterations in CNFs and PNFs apart from putative NF1 deficiency, our work confirms that methylation events are key molecular determinants of nerve tumor initiation, growth, and pain generation. How epigenetic regulation of kinase signaling affects cancer predisposition in these tumors remains unclear; however, recent data confirms that accumulating epigenetic alterations in a single field or region are associated with elevated cancer risk. Thus, our data lay the groundwork for future studies examining how epigenetic alterations affect PNF conversion into MPNSTs, as well as protective mechanisms that spare CNFs from cancerous progression or unchecked tumor growth. The identification of robust differences in the methylation profiles of CNFs versus PNFs also confirms their distinct biology, as well as laying the groundwork for future development of clinical biomarkers. Moreover, the
Chromatin conformational states differed significantly between CNFs and PNFs and were strongly linked to both site-specific and geographic-specific methylation events. These findings suggest that chromatin accessibility broadly affects gene expression in CNFs and PNFs. More work is needed to determine how epigenetic alterations affect regulatory genes that are known to contribute to tumor size and, ultimately, cancer predisposition. Based on our probe-based analysis of tumor tissue, we identified 34 CpG methylation sites that were statistically correlated with CNF size. Unfortunately, the genes corresponding to the individual methylation probe sites could not be identified with statistical confidence, nor could we link these methylation events with specific biological processes or signaling pathways. Regardless, these data confirm that CpG methylation influences CNF tumor size, possibly through a novel mechanism. More work is needed in this area.

Our data confirms that CNFs and PNFs strongly exhibit differential methylation at two established DMRs (i.e. DMR1 and DMR2) that are situated immediately upstream of the MAP2K3 transcriptional start site. This pattern of differential methylation resulted in upregulated expression of M KK3 and p38 in CNFs, whereas in PNFs the reciprocal effect was observed with downregulated expression (Fig. 5). This effect was consistent within and across tumor types despite expected signaling heterogeneity from analyzing whole tumor tissue from multiple subjects. The cell types that contributed to the observed differences in methylation profiles could not be determined. Unfortunately, deconvolution analysis is dependent on cell type-specific profiles which are lacking for NF1-deficient neurofibromas.

MAP2K3 was previously identified as a candidate imprinted gene in the context of NF1 deficiency, but the roles of its upstream DMRs are not well characterized. DMR1 is generally thought to regulate expression of an alternative coding region with sequence homology to exon 1, whereas DMR 2 regulates exon 1 directly. The importance of alternative exon expression in cancer is increasingly being recognized as it has been used to identify breast cancer subtypes using RNAseq data from the The Cancer Genome Atlas (TCGA) Breast Invasive Carcinoma (BRCA) cohort. DNA methylation status was also shown to affect expression of alternative exons in the sphingosine 1-phosphate (SPHK1) gene in gastroesophageal cancer. Apart from these studies, the impact of alternative exon expression on tumorigenesis has not been well described, nor has the role of methylation in defining which MAP2K3 exon is preferentially expressed.

Our work extends these important findings by identifying alternative exon utilization as a potential regulatory mechanism for the M KK3/ p38 signaling axis. M KK3/p38 is a critical pathway that couples RAS-mediated growth and proliferation with inflammation (e.g. EGR1) and chromatin remodeling (e.g. SWI-SNF). More broadly, these data strongly point towards epigenetic control of RAS signaling fates downstream of NF1. We propose a schema where p38 activation in response to cellular stress and cytokine signaling inputs is reinforced in CNFs, whereas PNFs appear to signal predominantly through RAS/MEK/ERK leading to growth and proliferation (Fig. 6-schematic). Future studies are needed to better define the implications of p38 activation in neurofibromas and their various cellular constituents. It is important to note, however, that crosstalk between the M KK3/p38 and RAS/MAPK signaling pathways has not been extensively studied. Prior work suggests a potential inhibitory role for RAS/ERK in mitigating
p38-mediated inflammation\textsuperscript{43}. Interestingly, p38 is not typically activated in response to mitogenic stimuli, but we observed a high degree of correlation between pp38 and pERK expression. These results suggest that differential methylation may enhance crosstalk between MKK3/p38 and RAS/ERK leading to mixed signaling effects in the context of NF1 deficiency.

Proof of this concept comes from our observation that upregulated MKK3 expression, in turn, correlated with both p38 expression (p38) and activation (pp38) indicating strong epigenetic reinforcement of the MKK3/ p38 axis in CNFs (Fig. 4). Two expected results of p38 activation are activation of the MKK3/p38/EGR1 inflammatory cascade\textsuperscript{44} and changes in chromatin conformation mediated through the SWI-SNF complex family\textsuperscript{45}. Relevant to the role of EGR1 in the pro-inflammatory response, it is intriguing that in our unbiased gene set enrichment analysis we identified inflammatory mediator regulation of TRP channels and phospholipase D signaling as the most significant altered signaling pathways related to DMRs (Fig. 4a), granted EGR1, itself, was not found to be differentially methylated (data not shown). Pain is a constant feature of CNFs and PNFs leading to significant morbidity. Pain signaling in nerve tumors is not well understood and difficult to manage, clinically. These data identify a potentially novel mechanism for epigenetic regulation of pain signaling in nerve tumors and a targetable signaling axis in MKK3/p38.

p38 is involved in the direct recruitment of SWI/SNF complexes to gene promoters resulting in chromatin modification and enhanced expression\textsuperscript{46}. Although the methylation states of SWI/SNF complex family member DMRs were not discordant between CNFs and PNFs, it is plausible that reinforced MKK3/p38 signaling would exert its effect through SWI/SNF leading to the observed conformational changes. Further studies are needed to determine how SWI/SNF affects expression of genes involved in growth, proliferation, and inflammation. Moreover, the effects of targeting p38 may be amplified by expected loss of recruitment of SWI/SNF complexes to target genes.

**Conclusion**

The epigenetic distinctions between CNFs and PNFs extend from the level of chromatin conformational change down to altered expression of genes that regulate or modulate RAS signaling. These findings are intriguing given that the analyzed tumors arose in the context of RAS deregulation as a result of NF1-deficiency. Based on KEGG pathway analysis, it is likely that methylation events are involved in regulation of pain signaling down to the level of inflammatory mediator production. More work is needed in many aspects of neurofibroma epigenetics, including studies targeting p38 and its downstream effectors. As such, we present a new signaling paradigm where differential methylation between tumor types results in reinforcement of inflammatory signaling in CNFs, and classical RAS/MEK/ERK activation towards growth in PNFs.

**Methods**

**Trial participants and sample collection**
45 cutaneous neurofibromas, 17 plexiform neurofibromas, and 9 normal skin and nerve samples were collected from individuals with a confirmed diagnosis of Neurofibromatosis Type 1. These samples were collected prospectively under an approved Spectrum Health/Van Andel Research Institute IRB protocol (SH/VAI IRB#2014–295) (NCT02777775). Additional specimens were analyzed according to ethical standards and under a Johns Hopkins Hospital (JHH) institutional review board (IRB)-approved protocol (JH IRB # J1649, PI Pratilas). The JH NF1 biospecimen repository is supported by a grant from the Neurofibromatosis Therapeutic Acceleration Program (NTAP, n-tap.org), to C.A.P. Analysis by Sage Bionetworks is supported through the Neurofibromatosis Therapeutic Acceleration Program (NTAP, n-tap.org). Informed consent was obtained from all participants. Tumor samples were isolated by microdissection to remove adjacent normal tissue then snap frozen in liquid nitrogen and stored at -80 °C. Quality parameters included assessment of percent content (> 95%) and viability (> 90% nuclear viability) by H/E staining. Biospecimen handling was performed according to BRISQ guidelines.

**5mC interrogation by Infinium MethylationEPIC array**

To extract DNA, frozen tissue was manually dissected into small pieces and homogenized by bead beating (Lysing Matrix D; MP Biomedicals) in UltraPure Phenol:Chloroform:Isoamyl Alcohol (ThermoFisher) according to the manufacturer’s protocol. DNA was quantified by Qubit fluorometry (Life Technologies) and 500 ng of DNA from each sample was bisulfite converted using the Zymo EZ DNA Methylation Kit (Zymo Research, Irvine, CA USA) following the manufacturer’s protocol using the specified modifications for the Illumina Infinium Methylation Assay. After conversion, all bisulfite reactions were cleaned using the Zymo-Spin binding columns and eluted in 12 uL of Tris buffer. Following elution, BS converted DNA was processed through the EPIC array protocol. The EPIC array contains > 850K probes querying methylation sites including CpG islands and non-island regions, RefSeq genes, ENCODE open chromatin, ENCODE transcription factor binding sites, and FANTOM5 enhancers. To perform the assay, 7uL of converted DNA was denatured with 1 ul 0.4N sodium hydroxide. DNA was then amplified, hybridized to the EPIC bead chip, and an extension reaction was performed using fluorophore labeled nucleotides per the manufacturer’s protocol. Array beadchips were scanned on the Illumina iScan platform and probe specific calls were made using Illumina Genome Studio software.

**EPIC methylation array data pre-processing**

Data were analyzed using a modified workflow that is similar to the ChAMP methylation array analysis procedure in R (v3.5.1). Briefly, samples were filtered for probes with poor or skewed intensities (detection P-value < 0.01) and entire samples were removed from the dataset if they contained > 10% failed probes. One sample exceeded the aforementioned filtering criteria and was removed from the dataset resulting in 70 total samples. Next, probes that have previously been identified to skew downstream differential methylation analyses (SNP probes, cross-reactive probes with other genomic regions, etc.) were removed in addition to probes that target sex chromosomes. A batch effect was detected based on SVD analysis and corrected using the sva (v3.30.1) package in R. In total, 717,148 probes were analyzed for differential methylation across tissue types.

**Differential methylation analysis**
Differentially methylated loci between cutaneous and plexiform neurofibromas were identified using a hierarchical generalized linear mixed model (GLMM) approach with a logit link function as implemented in glmmTMB (v0.2.2) on the pre-processed beta values. Partially repeated tissue sampling was modeled as a random effect with patient nested within methylation array slide unless specified otherwise. Group-level differences were determined using a likelihood ratio test (LRT) with a significance threshold of \( q < 0.05 \). False discovery rate adjustment was done using the Benjamini-Hochberg procedure. Models were filtered out for downstream analysis if they failed to converge. In total, 31,201 probes were found to be differentially methylated between cutaneous and plexiform neurofibromas. Differentially methylated regions were called using DMRcate (v1.18.0). Results from glmmTMB were wrangled into a suitable data structure as input for DMRcate by using the Wald statistic as the stat and a quasi-beta fold-change using the exponentiated model estimates for each probe. Default parameters were used for DMRcate with the bandwidth scaling factor (C parameter) set to 2. To identify differentially methylated loci associated with cutaneous neurofibroma size, a GLMM with a logit link was fitted, adjusting for age and sex differences and a random intercept term for partially repeated tissue sampling. Significant associations \( (q < 0.05) \) between CNF size in millimeters and probe-level methylation were determined as described above. A total of 188 loci were found to be significant. Positive or negative correlations were computed on significant probes using Kendall’s Tau. False discovery rate was controlled using the Benamini-Hochberg procedure and significant correlations were determined at a \( q < 0.05 \) threshold. Significantly correlated probes were filtered on a delta Beta-value (maximum Beta-value minus the minimum Beta-value) of 0.2, resulting in 34 loci.

**Inference of chromatin conformation from EPIC methylation arrays**

Chromatin compartments were computed at 100 kb resolution as previously described and implemented in compartmap (v1.65.71). Briefly, pre-processed M-values were subset to “open sea” CpG probes (at least 4 kb away from annotated CpG island) and masked probes that were found in at least 50% of samples were imputed using k-nearest neighbor via the impute (v1.59.0) R package. Next, loci were median summarized in 100 kb bins. Group-level compartments were inferred by computing Pearson correlations of summarized bins and the first principal component of the correlation matrix. A/B compartments correspond to positive (open chromatin) and negative (closed chromatin) eigenvalues, respectively. Genome-wide discordant compartments were identified by comparing the sign of the eigenvalue for overlapping genomic bins and filtering out those with small absolute eigenvalues \((> 0.02)\). In total, we identified 2937 discordant chromatin compartments between plexiform and cutaneous neurofibromas. Results were plotted using circlize (v0.4.8).

**Pathway and GO term enrichment**

Enrichment of pathways and gene ontology (GO) terms was performed using the gometh function within the missMethyl (v1.16.0) package in R. Briefly, gometh considers the relatively uneven density of loci covered on the Infinium methylation arrays and utilizes this information when computing enrichment, similar to the approach goseq uses for RNA-seq. Significant CpGs were identified as described above and
the background probe set was derived following pre-processing. Significant GO terms and KEGG pathways were determined using a \( q < 0.05 \) threshold. Results were plotted using ggplot2 (v3.2.1).

**Tissue purity estimates**

Tissue purity was estimated by PAMES (v0.2.3) and annotations built for computing informative sites using IlluminaHumanMethylationEPICanno.ilm10b2.hg19 (v0.6.0). Cutaneous neurofibromas were compared against normal skin samples and plexiform neurofibromas were compared against normal nerve. Results were plotted using ggplot2 (v3.2.1).

**Copy number estimation from EPIC methylation arrays**

Copy number alterations were computed using SeSAMe (v1.3.2) with minor modifications for plotting functionality. Briefly, data were processed using the “open SeSAMe” procedure, producing a signal set object. Next, samples were segmented and called for copy number differences, comparing CNFs to normal skin and PNFs to normal nerve. The genome annotation used was hg19.

**RNA-sequencing data analysis**

Paired-end, raw neurofibroma and plexiform neurofibroma RNA-seq data were downloaded from syn4939902. Sequencing lanes were merged, followed by alignment with STAR (v2.7.0f) to b37 (downloaded from the GATK resource bundle-https://software.broadinstitute.org/gatk/download/bundle), using the Gencode v19 annotations). Alignment was performed using default parameters with the following modifications: --twopassMode Basic, --outSAMtype BAM SortedByCoordinate, and --quantMode GeneCounts. Reverse-stranded gene counts were read into R (v3.6.1) using edgeR (v3.27.14), excluding sample 2–025 due to sample quality. Gene counts were restricted to known, protein coding genes and lincRNA. Samples were further filtered to genes that had greater than 1 count per million (CPM) in at least 3 samples. Libraries were normalized using the trimmed mean of M-values method. Dimensionality reduction was performed using the prcomp function (v3.6.1) on the filtered log2 CPM and plotted using ggplot2 (v3.2.1).

**Western Blotting**

For protein analysis, samples were divided into methylation high, methylation intermediate, and methylation low groups based on the beta values across MAP2K3 DMR1 and samples from each group were randomly chosen. Protein lysates were prepared by manually homogenizing frozen tissue in RIPA buffer containing protease and phosphatase inhibitor cocktails (Roche). Proteins were separated on a 4–20% TGX SDS-PAGE gel (Bio-Rad) and transferred to a PVDF membrane (Invitrogen). Blots were blocked in 5% dry milk in TBST buffer (20 mmol/L Tris-HCl pH 7.4, 150 mmol/L NaCl, 0.1% Tween-20) and incubated at 4 °C overnight in primary antibody; MKK3 (Cell Signaling #5674), p38 (Cell Signaling #9219), phospho-p38 (Cell Signaling # 4511), phospho-ERK1/2 (Cell Signaling #9101), and β-Actin (Cell Signaling #3700). Densitometry was done in ImageJ.

**Data availability**
Raw and processed EPIC array data are available from Synapse: syn4939910. Raw RNA-seq fastq data were downloaded from syn4939902.

Statistical Methods

Pairwise comparisons of beta regressions calculated by betareg (v3.1-2) were done using emmeans (v1.4.2). For correlation analysis, normality was first assessed by a Shapiro-Wilk normality test. Data following a normal distribution were analyzed by Pearson's product-moment correlation, while non-normally distributed data were analyzed by Spearman's rank correlation rho. For all correlation plots, data were fit by stat_smooth using loess with span = 1 using ggplot2 (v3.2.1). All analysis were done using R (v3.6.1).

Declarations

Data Availability

All data generated or analyzed during this study are included in this published article and its supplementary information files or are available from the corresponding author upon reasonable request. Statistical Source Data underlying all figures are provided as a separate file with a tab for each panel and the unprocessed western blots as Source Data. A Nature Research Reporting Summary for this article is available as a Supplementary Information file.

Acknowledgments

We would like to thank all patients who have donated samples for this study. This publication was supported by an agreement from The Johns Hopkins University School of Medicine and the Neurofibromatosis Therapeutic Acceleration Program (NTAP). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of The Johns Hopkins University School of Medicine. The authors thank the Van Andel Genomics Core for providing facilities and services.

Author Contributions

J.L.G., B.K.J., C.R.G., and M.R.S. designed the study. J.L.G. and B.K.J. performed research and data analysis. P.S.D., C.J.E., and S.C. harvested tissue. K.P. and C.A.P. contributed samples, clinical data, and analysis. M.A. advised on experimental design. T.J.T. advised on bioinformatic analysis. J.L.G., B.K.J., C.R.G., and M.R.S wrote the manuscript with contributions from all authors. M.R.S. provided overall study oversight. All authors approved the manuscript.

Competing Interests
None of the authors have any competing interest disclosures. None of the authors have any competing financial or non-financial interests to disclose.

References

1. Kim, A., et al. Malignant Peripheral Nerve Sheath Tumors State of the Science: Leveraging Clinical and Biological Insights into Effective Therapies. *Sarcoma* 2017, 7429697 (2017).

2. Thomas, L., Kluwe, L., Chuzhanova, N., Mautner, V. & Upadhyaya, M. Analysis of NF1 somatic mutations in cutaneous neurofibromas from patients with high tumor burden. *Neurogenetics* 11, 391-400 (2010).

3. Laycock-van Spyk, S., Thomas, N., Cooper, D.N. & Upadhyaya, M. Neurofibromatosis type 1-associated tumours: their somatic mutational spectrum and pathogenesis. *Hum Genomics* 5, 623-690 (2011).

4. Cannon, A., et al. Cutaneous neurofibromas in Neurofibromatosis type I: a quantitative natural history study. *Orphanet J Rare Dis* 13, 31 (2018).

5. Miller, S.J., et al. Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene. *EMBO Mol Med* 1, 236-248 (2009).

6. Asai, A., et al. High-resolution 400K oligonucleotide array comparative genomic hybridization analysis of neurofibromatosis type 1-associated cutaneous neurofibromas. *Gene* 558, 220-226 (2015).

7. Holtkamp, N., et al. Subclassification of nerve sheath tumors by gene expression profiling. *Brain Pathol* 14, 258-264 (2004).

8. Le, L.Q., Shipman, T., Burns, D.K. & Parada, L.F. Cell of origin and microenvironment contribution for NF1-associated dermal neurofibromas. *Cell Stem Cell* 4, 453-463 (2009).

9. Chen, Z., et al. Cells of origin in the embryonic nerve roots for NF1-associated plexiform neurofibroma. *Cancer Cell* 26, 695-706 (2014).

10. Staser, K., Yang, F.C. & Clapp, D.W. Mast cells and the neurofibroma microenvironment. *Blood* 116, 157-164 (2010).

11. Yang, F.C., et al. Nf1-dependent tumors require a microenvironment containing Nf1+/– and c-kit-dependent bone marrow. *Cell* 135, 437-448 (2008).

12. Harder, A., et al. Methylation analysis of the neurofibromatosis type 1 (NF1) promoter in peripheral nerve sheath tumours. *Eur J Cancer* 40, 2820-2828 (2004).

13. Rohrich, M., et al. Methylation-based classification of benign and malignant peripheral nerve sheath tumors. *Acta Neuropathol* 131, 877-887 (2016).

14. Ortonne, N., et al. Cutaneous neurofibromas: Current clinical and pathologic issues. *Neurology* 91, S5-S13 (2018).

15. Evans, D.G., Huson, S.M. & Birch, J.M. Malignant peripheral nerve sheath tumours in inherited disease. *Clin Sarcoma Res* 2, 17 (2012).
16. Pollard, K., et al. A clinically and genomically annotated nerve sheath tumor biospecimen repository. bioRxiv, 2019.2012.2019.871897 (2019).
17. Laurent, L., et al. Dynamic changes in the human methylome during differentiation. Genome Res 20, 320-331 (2010).
18. Doi, A., et al. Differential methylation of tissue- and cancer-specific CpG island shores distinguishes human induced pluripotent stem cells, embryonic stem cells and fibroblasts. Nat Genet 41, 1350-1353 (2009).
19. Vanderkraats, N.D., Hiken, J.F., Decker, K.F. & Edwards, J.R. Discovering high-resolution patterns of differential DNA methylation that correlate with gene expression changes. Nucleic Acids Res 41, 6816-6827 (2013).
20. Zhou, W., et al. DNA methylation loss in late-replicating domains is linked to mitotic cell division. Nat Genet 50, 591-602 (2018).
21. Sun, W., et al. A phase 1 study of azacitidine combined with chemotherapy in childhood leukemia: a report from the TACL consortium. Blood 131, 1145-1148 (2018).
22. Lieberman-Aiden, E., et al. Comprehensive mapping of long-range interactions reveals folding principles of the human genome. Science 326, 289-293 (2009).
23. Dixon, J.R., et al. Chromatin architecture reorganization during stem cell differentiation. Nature 518, 331-336 (2015).
24. Dileep, V., et al. Rapid Irreversible Transcriptional Reprogramming in Human Stem Cells Accompanied by Discordance between Replication Timing and Chromatin Compartment. Stem Cell Reports 13, 193-206 (2019).
25. Sanborn, A.L., et al. Chromatin extrusion explains key features of loop and domain formation in wild-type and engineered genomes. Proc Natl Acad Sci U S A 112, E6456-6465 (2015).
26. Fortin, J.P. & Hansen, K.D. Reconstructing A/B compartments as revealed by Hi-C using long-range correlations in epigenetic data. Genome Biol 16, 180 (2015).
27. Rieley, M.B., et al. Variable expression of neurofibromatosis 1 in monozygotic twins. Am J Med Genet A 155A, 478-485 (2011).
28. Sorkin, L.S., et al. MKK3, an upstream activator of p38, contributes to formalin phase 2 and late alldynia in mice. Neuroscience 162, 462-471 (2009).
29. Lee, J.C., et al. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 372, 739-746 (1994).
30. Beyaert, R., et al. The p38/RK mitogen-activated protein kinase pathway regulates interleukin-6 synthesis response to tumor necrosis factor. EMBO J 15, 1914-1923 (1996).
31. Li, W., et al. A methylation-phosphorylation switch determines Plk1 kinase activity and function in DNA damage repair. Sci Adv 5, eaau7566 (2019).
32. Brancho, D., et al. Mechanism of p38 MAP kinase activation in vivo. Genes Dev 17, 1969-1978 (2003).
33. Chen, G., Hitomi, M., Han, J. & Stacey, D.W. The p38 pathway provides negative feedback for Ras
proliferative signaling. *J Biol Chem* **275**, 38973-38980 (2000).

34. Dombi, E., *et al.* Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform
Neurofibromas. *N Engl J Med* **375**, 2550-2560 (2016).

35. Yan, P.S., *et al.* Mapping geographic zones of cancer risk with epigenetic biomarkers in normal breast
tissue. *Clin Cancer Res* **12**, 6626-6636 (2006).

36. Shen, L., *et al.* MGMT promoter methylation and field defect in sporadic colorectal cancer. *J Natl
Cancer Inst* **97**, 1330-1338 (2005).

37. Jin, Z., *et al.* A multicenter, double-blinded validation study of methylation biomarkers for progression
prediction in Barrett’s esophagus. *Cancer Res* **69**, 4112-4115 (2009).

38. Kondo, Y., *et al.* Genetic instability and aberrant DNA methylation in chronic hepatitis and cirrhosis–A
comprehensive study of loss of heterozygosity and microsatellite instability at 39 loci and DNA
hypermethylation on 8 CpG islands in microdissected specimens from patients with hepatocellular
carcinoma. *Hepatology* **32**, 970-979 (2000).

39. Lee, Y.C., *et al.* Revisit of field cancerization in squamous cell carcinoma of upper aerodigestive tract:
better risk assessment with epigenetic markers. *Cancer Prev Res (Phila)* **4**, 1982-1992 (2011).

40. Tuskan, R.G., *et al.* Real-time PCR analysis of candidate imprinted genes on mouse chromosome 11
shows balanced expression from the maternal and paternal chromosomes and strain-specific
variation in expression levels. *Epigenetics* **3**, 43-50 (2008).

41. Imamura, T., *et al.* CpG island of rat sphingosine kinase-1 gene: tissue-dependent DNA methylation
status and multiple alternative first exons. *Genomics* **76**, 117-125 (2001).

42. Matula, K., *et al.* Regulation of cellular sphingosine-1-phosphate by sphingosine kinase 1 and
sphingosine-1-phosphohyphosphate lyase determines chemotherapy resistance in gastroesophageal cancer.
*BMC Cancer* **15**, 762 (2015).

43. Xiao, Y.Q., *et al.* Cross-talk between ERK and p38 MAPK mediates selective suppression of pro-
inflammatory cytokines by transforming growth factor-beta. *J Biol Chem* **277**, 14884-14893 (2002).

44. Ko, S.W., *et al.* Selective contribution of Egr1 (zif/268) to persistent inflammatory pain. *J Pain* **6**, 12-
20 (2005).

45. Tang, L., Nogales, E. & Ciferri, C. Structure and function of SWI/SNF chromatin remodeling
complexes and mechanistic implications for transcription. *Prog Biophys Mol Biol* **102**, 122-128
(2010).

46. Simone, C., *et al.* p38 pathway targets SWI-SNF chromatin-remodeling complex to muscle-specific
loci. *Nat Genet* **36**, 738-743 (2004).

**Figures**
Figure 1

CNFs and PNFs are epigenetically distinct tumor types. (a) Clinical presentation of a CNF with H/E stain (20X/100X magnification shown); versus (b) PNF resected from deep shoulder location (T2-weighted MRI image; H/E 20X/100X shown). (c) Principal component analysis of RNAseq expression data comparing CNFs (purple) and PNFs (green) neurofibromas. (d) Copy number analysis of CNFs versus PNFs. (e) Unsupervised heirarchical cluster analysis of methylation probesets (i.e. beta values) demonstrating unique CNF and PNF methylation profiles.
Chromatin architecture analysis reveals distinct structural and site-specific methylation events. (a) Genome-wide chromatin compartment calling (X-chromosome excluded) comparing CNFs to PNFs. (b) DMR analysis of overlapping promoter and enhancer space between CNFs and PNFs. Top 100 significant DMR sites shown. (c) Chromatin compartment concordance is depicted as the fraction of CNF and PNF compartment overlap at 100kb resolution. (d) Chromosome 17 was the most differentially methylated chromosome. Chromosome-specific analysis of promoter and enhancer space shown. Red bar indicates position of the NF1 gene. (e) Chromatin structural analysis demonstrating the distribution of DMR calls in topographic CpG categories (i.e. shelves, shores, islands, promoters and enhancers).
Figure 3

Differential methylation correlates with CNF tumor size. Graphical comparison of methylation levels (i.e. beta values) versus CNF size (mm) at DMRs determined to be significantly correlated with measured size of CNF tumors.
Figure 4

Functional annotation of significant DMRs reveals differential methylation at alternative MAP2K3 exons leading to coordinated MKK3 expression. (a) KEGG pathway analysis of CNF and PNF methylation profiles confirms that multiple pathways are regulated epigenetically including growth factor, inflammatory, pain signaling and oxytocin pathways. (b and c) Differential methylation was observed in upstream regulatory sites in MAP2K3 that control alternative leading exon expression. (d) Western blot analysis of MKK3 protein (Actin loading control). Beta values for tumor-type DMRs (DMR1/DMR2) shown below. (e) DMR1 beta values correlate strongly with MKK3/Actin ratio expression values (p<0.01; r=-0.846).
Figure 5

MKK3/P38 signaling axis is epigenetically reinforced through methylation events in critical regulatory regions. (a) p38 expression (WB) shown between CNFs and PNFs. P38 expression strongly correlates with (b) promoter methylation in MAPK14 (beta values shown; p=0.038; r=-0.6). (c,d) Phospho-p38 expression and phospho-ERK expression are demonstrated by western blot (c) and were significantly correlated (d)(p=0.006; r=0.70).
Proposed differential signaling schema comparing PNFs and CNFs. Although both RAS/MEK/ERK and RAS/MKK3/P38 signaling occurs in both tumor types, RAS activation results in differential signaling strength and fidelity through RAS/MEK in PNFs (left panel) and, alternatively, RAS/MKK3/P38 in CNFs (right panel). CNFs divert RAS activation through MKK3 thereby enhancing the cellular response to stress and inflammation that is mediated by MKK3/p38, whereas the downstream impact in RAS/MEK dependent PNFs is unchecked growth and proliferation (left). CNFs still maintain growth and proliferation signaling through RAS/ERK or p38/ERK, but strongly exhibit a pro-inflammatory phenotype and are characterized by broad chromatin remodeling (right).

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- Supplemental.pdf